Olson M F, Tsao J, Pon D J, Schimmer B P
Banting and Best Department of Medical Research Department of Pharmacology, University of Toronto, Ontario, Canada.
Mol Endocrinol. 1991 Jan;5(1):34-41. doi: 10.1210/mend-5-1-34.
Mutant clones resistant to ACTH-induced desensitization of adenylyl cyclase (Y1DR) were previously isolated from the Y1 mouse adrenocortical tumor cell line. In this study, both parental Y1 cells (Y1DS) and a Y1DR mutant were transfected with a gene encoding the mouse beta 2-adrenergic receptor, and transfectants isolated from both Y1DS and Y1DR cells were shown to express beta 2-adrenergic receptors. These transfectants responded to the beta-adrenergic agonist isoproterenol with increases in adenylyl cyclase activity and steroidogenesis and changes in cell shape. The transfectants were analyzed to determine whether the Y1DR mutation was specific for ACTH-induced desensitization of adenylyl cyclase or also affected desensitization of adenylyl cyclase via the beta 2-adrenergic receptor. Treatment of intact Y1DS transfectants with isoproterenol caused a rapid desensitization of the adenylyl cyclase system to further stimulation by the beta-adrenergic agonist. Treatment of intact cells with isoproterenol did not affect ACTH-stimulated adenylyl cyclase activity, indicating that desensitization was agonist specific or homologous. Y1DR transfectants were resistant to the desensitizing effects of isoproterenol in intact cells as well as in cell homogenates. These results indicate that the mutation in Y1DR transfectants affects a component that is common to the pathways of isoproterenol-induced desensitization and ACTH-induced desensitization of adenylyl cyclase. As determined using the hydrophilic beta-receptor antagonist CGP-12177, isoproterenol caused a rapid sequestration of cell surface receptors in both Y1DS and Y1DR transfectants. From these results we infer that the DR phenotype does not arise from mutations affecting receptor sequestration and that receptor number does not limit the response to isoproterenol in these transfectants.
先前从Y1小鼠肾上腺皮质肿瘤细胞系中分离出对促肾上腺皮质激素(ACTH)诱导的腺苷酸环化酶脱敏具有抗性的突变克隆(Y1DR)。在本研究中,将编码小鼠β2 - 肾上腺素能受体的基因转染到亲代Y1细胞(Y1DS)和Y1DR突变体中,并且从Y1DS和Y1DR细胞中分离出的转染子均显示表达β2 - 肾上腺素能受体。这些转染子对β - 肾上腺素能激动剂异丙肾上腺素产生反应,腺苷酸环化酶活性、类固醇生成增加以及细胞形态发生变化。对这些转染子进行分析,以确定Y1DR突变是特异性针对ACTH诱导的腺苷酸环化酶脱敏,还是也影响通过β2 - 肾上腺素能受体介导的腺苷酸环化酶脱敏。用异丙肾上腺素处理完整的Y1DS转染子会导致腺苷酸环化酶系统对β - 肾上腺素能激动剂的进一步刺激迅速脱敏。用异丙肾上腺素处理完整细胞不影响ACTH刺激的腺苷酸环化酶活性,表明脱敏是激动剂特异性的或同源的。Y1DR转染子在完整细胞以及细胞匀浆中均对异丙肾上腺素的脱敏作用具有抗性。这些结果表明,Y1DR转染子中的突变影响了异丙肾上腺素诱导的脱敏途径和ACTH诱导的腺苷酸环化酶脱敏途径中的一个共同成分。使用亲水性β受体拮抗剂CGP - 12177测定,异丙肾上腺素在Y1DS和Y1DR转染子中均导致细胞表面受体的快速内吞。从这些结果我们推断,DR表型并非源于影响受体内吞的突变,并且受体数量并不限制这些转染子对异丙肾上腺素的反应。